Literature DB >> 5440591

Prognosis in Hodgkin's disease.

.   

Abstract

Entities:  

Mesh:

Year:  1970        PMID: 5440591      PMCID: PMC1699990     

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


× No keyword cloud information.
  10 in total

1.  Studies on delayed hypersensitivity in Hodgkin's disease.

Authors:  A C AISENBERG
Journal:  J Clin Invest       Date:  1962-11       Impact factor: 14.808

2.  A comparative study of the incidence of anergy in patients with carcinoma, leukemia, hodgkin's disease and other lymphomas.

Authors:  D LAMB; F PILNEY; W D KELLY; R A GOOD
Journal:  J Immunol       Date:  1962-10       Impact factor: 5.422

3.  Reed-Sternberg-like cells in infectious mononucleosis.

Authors:  R J Lukes; B H Tindle; J W Parker
Journal:  Lancet       Date:  1969-11-08       Impact factor: 79.321

4.  Pyrogen in the urine of febrile patients with Hodgkin's disease.

Authors:  J E Sokal; K Shimaoka
Journal:  Nature       Date:  1967-09-09       Impact factor: 49.962

5.  The treatment of the reticuloses.

Authors:  H F Hope-Stone
Journal:  Br J Radiol       Date:  1969-10       Impact factor: 3.039

6.  Hodgkin's disease: a follow-up study of patients surviving more than twenty years after the original diagnosis.

Authors:  H F Smetana
Journal:  J Pathol       Date:  1969-08       Impact factor: 7.996

7.  Prolonged observations on variations in the serum copper in Hodgkin's disease.

Authors:  R L Warren; A M Jelliffe; J V Watson; C B Hobbs
Journal:  Clin Radiol       Date:  1969-07       Impact factor: 2.350

8.  The pathology and nomenclature of Hodgkin's disease.

Authors:  R J Lukes; J J Butler
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

9.  Long-term results of palliative and radical radiotherapy of Hodgkin's disease.

Authors:  H S Kaplan
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

10.  Long-term results of radical radiotherapy in Hodgkin's disease.

Authors:  E C Easson
Journal:  Cancer Res       Date:  1966-06       Impact factor: 12.701

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.